Precision BioSciences recently unveiled its strategic priorities for 2026, placing a significant emphasis on advancing its clinical programs PBGENE-HBV and PBGENE-DMD.
PBGENE-HBV is currently in an ongoing Phase 1/2a ELIMINATE-B trial, with data updates expected to be disclosed at major medical conferences throughout 2026.
Meanwhile, PBGENE-DMD is on track to secure Investigational New Drug (IND) clearance in the first quarter of 2026 for its Phase 1/2 FUNCTION-DMD study, with initial data slated for release later in the year.
Financial Position
Precision BioSciences reported unaudited cash, cash equivalents, and restricted cash totaling approximately $137 million as of December 31, 2025. This strong financial position is expected to fuel critical clinical milestones all the way through 2028.
PBGENE-HBV Progress
Encouraging results from the ELIMINATE-B trial indicate positive dose-dependent effects, antiviral activity, and favorable safety profiles, pointing to the potential effectiveness of the gene editing therapy for chronic hepatitis B.
PBGENE-DMD Development
The PBGENE-DMD program offers a novel gene editing therapy for Duchenne Muscular Dystrophy, featuring a unique gene excision strategy targeting mutations in exons 45-55, showcasing Precision BioSciences' cutting-edge approach.
- Precision BioSciences is making significant strides in advancing its clinical programs, backed by promising outcomes.
- The safety and efficacy data from the ongoing trials signal the exciting potential of Precision BioSciences' gene editing therapies to drive transformative changes in the treatment landscape.
- The company's robust financial stability not only bodes well for achieving key milestones but also underscores its commitment to operational excellence in 2026.
Precision BioSciences remains steadfast in its commitment to developing innovative gene editing therapies for diseases with high unmet needs, with a particular focus on the PBGENE-HBV and PBGENE-DMD initiatives. The progress made through ongoing trials and the forthcoming data releases represent significant steps towards potentially groundbreaking treatment options for patients in need of advanced therapeutic solutions.